Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
19.53
-2.68 (-12.07%)
At close: Mar 31, 2025, 4:00 PM
19.58
+0.05 (0.26%)
After-hours: Mar 31, 2025, 7:29 PM EDT
Beam Therapeutics Revenue
In the year 2024, Beam Therapeutics had annual revenue of $63.52M, down -83.18%. Beam Therapeutics had revenue of $30.07M in the quarter ending December 31, 2024, a decrease of -90.49%.
Revenue (ttm)
$63.52M
Revenue Growth
-83.18%
P/S Ratio
25.31
Revenue / Employee
$131,507
Employees
483
Market Cap
1.58B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BEAM News
- 5 hours ago - Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - Invezz
- 4 days ago - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - GlobeNewsWire
- 10 days ago - Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha
- 21 days ago - Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity - Benzinga
- 21 days ago - Beam Therapeutics Announces Pricing of Underwritten Offering - GlobeNewsWire
- 21 days ago - Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts - GlobeNewsWire
- 5 weeks ago - Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences - GlobeNewsWire